Recruiting
Phase 1
Phase 2

Lactulose with Immunotherapy

Sponsor:

University of Chicago

Code:

NCT07354100

Conditions

Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Lactulose

Study Details

Brief summary:

The purpose of this study is to see if lactulose can improve the effectiveness of immunotherapy in patients with advanced cancer.

Conditions

Cancer

Study ID

NCT07354100

Start date

Dec 15, 2026

Status verified date

Jan, 2026

Completion date

Apr 13, 2029

Anticipated

Primary completion date

Apr 13, 2029

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Inclusion Criteria Phase I
  • Patients must have a histologically confirmed malignancy that is to receive exclusively ICIs (no chemotherapy or RT in combination) per standard of care during the time in which lactulose will be administered. This includes, but is not limited to, melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, mesothelioma, head and neck squamous cell carcinoma, classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, urothelial cancer, MSI/MMRd cancer, cancers with high tumor mutational burden (>=10 muts/mB), esophageal cancer, hepatocellular carcinoma, and renal cell carcinoma. Anti-PD-1 or anti-PD-L-1 therapy combinations with anti-LAG-3 or anti-CTLA-4 combinations are permitted.
  • Age ≥18 years. Because no dosing or adverse event data are currently available on the use of lactulose in combination with ICIs in patients <18 years of age, children are excluded from this study.
  • ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A).
  • Patients must be able to ingest liquids.
  • Inclusion Criteria Phase II
  • Patients must have a histologically confirmed cutaneous or mucosal melanoma. Uveal melanoma is excluded.
  • Measurable disease per RECIST 1.1.32
  • Documented primary or acquired resistance to anti-PD-1 and anti-CTLA4 therapy per SITC guidelines.21 Primary resistance is defined as disease progression after a minimum of 6 weeks of therapy, provided the patient has received at least two full cycles of treatment, and there has been no prior evidence of clinical benefit (partial response, complete response, or stable disease lasting at least 6 months). Acquired resistance is defined as disease progression after an initial clinical benefit while still on therapy or within 12 weeks of discontinuing therapy, provided the patient received at least two cycles and 6 weeks of therapy.
  • Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
  • Planned to receive standard ICI therapy (no RT/ICI or chemotherapy/ICI combinations).
  • Age ≥18 years. Because no dosing or adverse event data are currently available on the use of lactulose in combination with ICIs in patients <18 years of age, children are excluded from this study.
  • ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A).
  • Patients must be able to ingest liquids.

Exclusion Criteria:

  • Exclusion Criteria for Phase I
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to ICIs or lactulose.
  • Current serious concomitant illnesses include cardiovascular diseases (such as uncontrolled congestive heart failure, hypertension, cardiac ischemia, myocardial infarction, and severe cardiac arrhythmias), bleeding disorders, autoimmune diseases, severe obstructive or restrictive pulmonary diseases, active systemic infections, and inflammatory bowel disorders, including HIV or AIDS-related illnesses or active hepatitis B or C virus.
  • The ongoing use of systemic antibiotics or the previous use of antibiotics in the 2 weeks before enrollment.
  • Presence of a chronic intestinal disease (for example, celiac, or malabsorption) where the frequency of bowel movements would interfere with study assessments.
  • Absence of the large bowel.
  • The presence of absolute contraindications to lactulose administration includes galactosemia or other conditions that necessitate a low intake of galactose.
  • Expected to require any other form of systemic anti-neoplastic therapy while in the study (i.e., chemotherapy or radiation therapy).
  • Symptomatic CNS metastases and/or leptomeningeal involvement. Patients with CNS metastases and/or leptomeningeal involvement may participate if they are clinically stable, as judged by the enrolling investigator.
  • Has an active autoimmune disease or a documented history of autoimmune disease or syndrome that requires systemic steroids or immunosuppressive agents. Patients with vitiligo, type I diabetes, or resolved childhood asthma/atopy are exceptions to this rule.
  • A history of immune-related adverse events to ICIs that precludes the investigator from comfortably re-challenging with ICIs.
  • Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  • Exclusion Criteria for Phase II
  • Patients with a "currently active" second malignancy other than non-melanoma skin cancers. Patients are not considered to have a "currently active" malignancy if they have completed therapy and are free of disease for ≥ 2 years.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to ICIs or lactulose.
  • Current serious concomitant illnesses include cardiovascular diseases (such as uncontrolled congestive heart failure, hypertension, cardiac ischemia, myocardial infarction, and severe cardiac arrhythmias), bleeding disorders, autoimmune diseases, severe obstructive or restrictive pulmonary diseases, active systemic infections, and inflammatory bowel disorders, including HIV or AIDS-related illnesses or active hepatitis B or C virus.
  • The ongoing use of systemic antibiotics or the previous use of antibiotics in the 2 weeks before enrollment.
  • Presence of a chronic intestinal disease (for example, celiac, or malabsorption) where the frequency of bowel movements would interfere with study assessments.
  • Absence of the large bowel
  • The presence of absolute contraindications to lactulose administration includes galactosemia or other conditions that necessitate a low intake of galactose.
  • Expected to require any other form of systemic anti-neoplastic therapy while in the study (i.e., chemotherapy or radiation therapy).
  • Symptomatic CNS metastases and/or leptomeningeal involvement. Patients with CNS metastases and/or leptomeningeal involvement may participate if they are clinically stable, as judged by the enrolling investigator.
  • Has an active autoimmune disease or a documented history of autoimmune disease or syndrome that requires systemic steroids or immunosuppressive agents. Patients with vitiligo, type I diabetes, or resolved childhood asthma/atopy are exceptions to this rule.
  • A history of immune-related adverse events to ICIs that precludes the investigator from comfortably re-challenging with ICIs.
  • Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.

Study Design

Enrollment

55 participants

Anticipated

Allocation

Non randomized

Intervention Model

Sequential

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Phase 1 Arm

Patients with solid tumor cancers receiving routine immunotherapy will be enrolled to receive lactulose (10 mg daily).

experimental: Phase 2 Arm

o Patients with melanoma receiving routine immunotherapy will be enrolled to receive lactulose (10 mg daily).

Interventions

Lactulose

Lactulose 10 g daily with standard-of-care Immune checkpoint inhibitors (ICIs).

Primary outcome measure

  • Phase 1- [ Time Frame: Baseline to week 3 ]
  • Overall Response Rate [ Time Frame: Through study completion, an average of 2 years ]

Central Contacts and Locations

Central contacts

Clinical Trials Intake Intake

8557028222cancerclinicaltrials@bsd.uchicago.edu

Locations

University of Chicago Medicine Comprehensive Cancer Center

Recruiting

Chicago, Illinois, United States, 60637

More Information

Sponsor

University of Chicago

Last update posted

Jun 16, 2026

Last verified

Jan, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by University of Chicago on 2026-06-16.